{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Over+Age+60", "query": { "condition": "Over Age 60" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Over+Age+60&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T15:13:53.936Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06984640", "title": "Curcumin Supplementation for the Improvement of Diabetes-related Outcomes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Over Age 60", "Prediabetes or Overweight" ], "interventions": [ { "name": "Curcumin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Oklahoma State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 28, "start_date": "2023-03-16", "completion_date": "2025-02-13", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 1, "location_summary": "Stillwater, Oklahoma", "locations": [ { "city": "Stillwater", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT06984640" }, { "nct_id": "NCT00170768", "title": "Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Darifenacin", "type": "DRUG" }, { "name": "Oxybutynin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 150, "start_date": "2005-02", "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2008-01-23", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00170768" }, { "nct_id": "NCT00089050", "title": "Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "gemtuzumab ozogamicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": null, "start_date": "2004-05", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2011-11-30", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089050" }, { "nct_id": "NCT04827212", "title": "Companion: Sensor-based Two-way Communication for Physical Activity in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Exercise", "Physical Activity" ], "interventions": [ { "name": "Companion", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Northeastern University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "60 Years to 90 Years" }, "enrollment_count": 51, "start_date": "2021-03-16", "completion_date": "2022-12-13", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04827212" }, { "nct_id": "NCT02000596", "title": "1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab plus Pertuzumab", "type": "DRUG" }, { "name": "Hormonal Therapy with Anastrozole and Fulvestrant", "type": "DRUG" }, { "name": "Chemotherapy with Eribulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "FEMALE", "summary": "60 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2014-01", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2022-05-27", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02000596" }, { "nct_id": "NCT02758717", "title": "Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage IB Hodgkin Lymphoma", "Ann Arbor Stage II Hodgkin Lymphoma", "Ann Arbor Stage IIA Hodgkin Lymphoma", "Ann Arbor Stage IIB Hodgkin Lymphoma", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage IIIA Hodgkin Lymphoma", "Ann Arbor Stage IIIB Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IVA Hodgkin Lymphoma", "Ann Arbor Stage IVB Hodgkin Lymphoma", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 46, "start_date": "2016-05-13", "completion_date": "2025-09-13", "has_results": true, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 9, "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02758717" }, { "nct_id": "NCT03834688", "title": "Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 33, "start_date": "2020-01-13", "completion_date": "2024-07-26", "has_results": true, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 7, "location_summary": "Urbana, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Urbana", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834688" }, { "nct_id": "NCT00093470", "title": "Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Alkylating Agent-Related Acute Myeloid Leukemia", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Clinical Observation", "type": "PROCEDURE" }, { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2004-08-18", "completion_date": null, "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 339, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 228 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093470" }, { "nct_id": "NCT04188678", "title": "Resiliency in Older Adults Undergoing Bone Marrow Transplant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia", "Lymphoma", "Blood Cancer", "Myelodysplastic Syndrome", "Acute Myelogenous Leukemia", "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "Bone Marrow Transplant (BMT)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 126, "start_date": "2018-09-28", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04188678" }, { "nct_id": "NCT00121589", "title": "Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "Lutein", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 40, "start_date": "2005-07-14", "completion_date": "2007-08-15", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-06-27T15:13:53.936Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00121589" } ] }